Treprostinil

Treprostinil

CAT N°: 10162
Price:

From 146.00 124.10

Primary pulmonary hypertension (PPH) is a condition of unknown cause that is characterized by increasing pulmonary arterial and vascular resistance. Treprostinil is a stable analog of prostacyclin (Item No. 18220) that is used clinically for the treatment of PPH under the trade name Remodulin™. The structural modifications in treprostinil compared to prostacyclin increase the plasma half-life from 2 minutes to 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively.{13285} In addition to treprostinil’s direct vasodilatory effects, it also inhibits inflammatory cytokine (TNF?, IL-1?, IL-6, GM-CF) production by human alveolar macrophages in the sub-micromolar range by preventing NF-?B translocation to the nucleus.{12665}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 2-[[(1R,2R,3aS,9aS)-2,3,4,9,9a-hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]-acetic acid
  • Correlated keywords
    • primary pulmonary hypertension PPH arterial vascular resistance stable analogs prostacyclins increase plasma half-life vasodilatory inhibits inflammatory cytokines inhibition inhibitors GM-CF human alveolar macrophages NF-KB NF-.kappa. translocations nucleus NF-kappaB nfkb nf-kb NF-.kappa.B atherosclerosis Tyvasos Tyvaso® remodulin BW15AU BW-15AU LRX15 LRX-15 U62840 U 62840
  • Product Overview:
    Primary pulmonary hypertension (PPH) is a condition of unknown cause that is characterized by increasing pulmonary arterial and vascular resistance. Treprostinil is a stable analog of prostacyclin (Item No. 18220) that is used clinically for the treatment of PPH under the trade name Remodulin™. The structural modifications in treprostinil compared to prostacyclin increase the plasma half-life from 2 minutes to 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively.{13285} In addition to treprostinil’s direct vasodilatory effects, it also inhibits inflammatory cytokine (TNF?, IL-1?, IL-6, GM-CF) production by human alveolar macrophages in the sub-micromolar range by preventing NF-?B translocation to the nucleus.{12665}

We also advise you